Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Conclusions br Acknowledgement Work in the authors
2022-03-21

Conclusions Acknowledgement Work in the authors’ labs was funded by Natural Sciences and Engineering Research Council of Canada (OGP0194652 and OGP0041653) and Diabète Québec. Introduction Fifty years ago, Sydney Brenner proposed Caenorhabditis elegans as a useful model for the study of an
-
Prior to proceeding to the
2022-03-21

Prior to proceeding to the main tests, essential conditions were optimized. At first, we tested whether the parameters that were successful in inducing LacZ gene for the production of β-galactosidase enzymes in E. coli culture system in our previous study would be sufficient to induce LacZ gene in t
-
Irpex lacteus was well known as
2022-03-21

Irpex lacteus was well known as an edible and medicinal mushroom. It had been reported that I. lacteus could produce a thermostable α-galactosidase [17]. The reported α-galactosidase from I. lacteus, however, seemed to be unsuitable for the practical application due to its poor hydrolysis ability to
-
Phosphoramidon Disodium Salt mg br The potential of EPA Ffar
2022-03-21

The potential of EPA-Ffar4 signaling as a novel intervention for HFpEF Conclusions and future directions Optimization of ω3-PUFA/EPA-therapy based upon titration to achieve therapeutic levels: A pressing clinical challenge is to continue to define the benefit of ω3-PUFA/EPA-therapy. Recent ana
-
br Introduction The fibroblast growth
2022-03-21

Introduction The fibroblast growth factor receptor (FGFR) pathway is an important oncogenic driver in malignant cancer. It controls cellular processes such as cell proliferation, differentiation, migration, SYBR Safe DNA Gel Stain progression, metabolism, and survival. In non–small-cell lung can
-
Although drug monitoring is not usually requested
2022-03-18

Although drug monitoring is not usually requested, there are some cases where measurement of DOACs in dilution is useful, and of special help for managing patients at risk. These cases include the control of adherence to a therapeutic protocol, surveillance of drug accumulation risk in long term tr
-
Fatty acid amide hydrolase FAAH is
2022-03-18

Fatty (-)-Lobeline hydrochloride amide hydrolase (FAAH) is a membrane-bound enzyme which releases arachidonic acid and ethanolamine by breaking amide bond of AEA. It also controls the cellular uptake of AEA, by creating and maintaining an inward concentration gradient leading to AEA-facilitated dif
-
Under normal physiological conditions the body
2022-03-18

Under normal physiological conditions, the body has sufficient oxygen supply, so glucose can produce large amounts of ATP by aerobic oxidation and oxidative phosphorylation in cells. After SCI, hypoxia ischemia can occur in local tissue, leading to decreasing of intracellular oxygen partial pressure
-
br HO regulation and physiology The catabolism of cellular h
2022-03-18

HO-1: regulation and physiology The catabolism of cellular heme in humans and other species is mediated by the heme oxygenase (HO) family of enzymes (E.C. 1:14:99:3; heme-hydrogen donor:oxygen oxidoreductase). The HOs localize primarily to the endoplasmic reticulum (ER) where they serve, in conce
-
Anti apoptotic Bcl proteins have become attractive targets f
2022-03-18

Anti-apoptotic Bcl-2 proteins have become attractive targets for anti-cancer agents development, because they are associated with progression of a wide variety of human cancers., , The small-molecular Bcl-2 inhibitor venetoclax (ABT-199) () has been approved recently for the treatment of patients w
-
br Financial support This study was supported by Grant PH
2022-03-18

Financial support This study was supported by Grant PH-102-PP-11, PH-103-PP-11 from the National Health Research Institutes, Taiwan. Conflict of interest Please refer to the accompanying ICMJE disclosure forms for further details. Authors’ contributions Acknowledgements Introduction
-
A repertoire of cytotoxic payloads is increasing among those
2022-03-18

A repertoire of cytotoxic payloads is increasing; among those, MMAE has been utilized for the highly effective ADC brentuximab vedotin. However, the ADCs which utilized MMAE to target GCC in solid tumors have shown a poor efficacy suggesting that various tumor types respond differently to a given to
-
Compounds and were tested for pharmacodynamic effects in a
2022-03-18

Compounds , and were tested for pharmacodynamic effects in a mouse oral glucose tolerance test (oGTT) in wild-type and GPR120 deficient mice, and each compound demonstrated GPR120 mechanism-based effects. Data for compound is shown in , indicating mechanism-based reduction in glucose excursion a
-
br Author contributions br Acknowledgements The work was fin
2022-03-18

Author contributions Acknowledgements The work was financially supported by a grant from the Investigator-Initiated Studies Program (Ref. #38124) from Merck Sharp & Dohme, and, in part, from Research Grants Council of the Hong Kong Special Administrative Region, China (Ref. No.: 14110314), awa
-
Based on these findings we set out to
2022-03-18

Based on these findings, we set out to identify GPR109A agonists capable of biasing the receptor's signaling towards the functional anti-lipolytic and presumed therapeutic response, and away from the flushing side-effect pathways. Indeed, using recombinantly expressed GPR109A, two classes of compoun
11679 records 182/779 page Previous Next First page 上5页 181182183184185 下5页 Last page